Program

Conference Chairperson:
John T. Hunt, Bristol-Myers Squibb, Princeton, NJ

Scientific Program Committee:
Matthew A. Marx, Pfizer, San Diego, CA
Brent R. Stockwell, Columbia University, New York, NY
David A. Wink, National Cancer Institute, Bethesda, MD
Cheryl L. Zimmerman, University of Minnesota College of Pharmacy, Minneapolis, MN

February 8
6:30-8:00 p.m.	Keynote Lectures
	Introduction of Dr. Larry J. Marnett John T. Hunt, Bristol-Myers Squibb, Princeton, NJ Cyclooxygenase Inhibitors in Cancer Prevention and Treatment Larry J. Marnett, Vanderbilt University, Nashville, TN Introduction of Dr. Gregory L. Verdine Brent R. Stockwell, Columbia University, New York, NY Interrogation, Recognition, and Repair of Oxidative Damage in DNA Gregory L. Verdine, Harvard University, Cambridge, MA
8:00 – 9:00 p.m.	Welcome Dessert Reception

February 9
7:00 – 8:00 a.m.	Continental Breakfast
8:00 – 9:45 a.m.	Session 1: Chemistry in Support of Cancer Target ID and Validation
	Session Chair: Brent R. Stockwell, Columbia University, New York, NY Chemical Genetics and Cell Death Brent R. Stockwell Multi-dimensional Chemical Genetics Alexis Borisy, CombinatoRx, Inc., Cambridge, MA Title to be announced Benjamin F. Cravatt, Scripps, La Jolla, CA
9:45-10:15 a.m.	Coffee Break
10:15 a.m.-12:00 p.m.	Session 2: Chemistry in Support of Lead Discovery/Chemical Libraries
	Session Chair: Michael Foley, Broad Institute, Cambridge, MA Natural Product-based Librarires for Chemical Biology and Drug Discovery Derek S. Tan, Memorial Sloan-Kettering Cancer Center Title to be announced Michael Foley Achieving Synthetic Control When Nature Abandons Selectivity: Total Synthesis of Resveratrol-based Natural Products Scott A. Snyder, Columbia University, New York, NY
12:00 – 1:30 p.m.	Lunch on own or Professional Advancement Session
1:30 – 3:15 p.m.	Session 3: Chemistry in Support of Lead Discovery/Screening, Hit Validation, and Natural Products
	Session Chairperson: Steven E. Hall, Serenex, Durham, NC Development and Use of Nucleotide Affinity Columns to Identify Leads for Hsp90 and Other Nucleotide Utilizing Enzymes Steven E. Hall Title to be announced Jeremy Caldwell, Genomics Institute of the Novartis Research Foundation, San Diego, CA Beyond Natural Products: Function Oriented Synthesis and New Leads for Cancer and Overcoming Cancer Resistance Paul A. Wender, Stanford University, Stanford, CA
3:15 – 3:45 p.m.	Coffee Break
3:45 – 5:30 p.m.	Session 4: Chemistry in Support of Lead Discovery/Chemoinformatics
	Session Chairperson: To be announced High Throughput Kinase Profiling: Revealing the Relationship Between Chemical Structure and Kinase Interaction Patterns Patrick Zarrinkar, Ambit Biosciences, San Diego, CA A Systems Approach to Therapeutic Discovery John Westwick, Odyssey Thera, San Ramon, CA In Silico Discovery of Small Molecules Targeting Transcription Factors in Cancer Alan C. Rigby, Harvard Medical School, Boston, MA
5:30 – 7:30 p.m.	Poster Session A and Cocktail Reception

February 10
7:00 – 8:00 a.m.	Continental Breakfast
8:00 – 9:45 a.m.	Session 5: Chemistry in Support of Lead Optimization/Case Histories I
	Session Chair: Matthew Marx, Pfizer, San Diego, CA The Discovery of Novel Androgen Receptor Antagonists Aaron Balog, Bristol-Myers Squibb, Princeton, NJ GDC-0449: A Small Molecule Antagonist of the Hedgehog Pathway James Marsters, Genentech, Inc., South San Francisco, CA Discovery of Eltrombopag, a Small-Molecule, Oral Thrombopoietin Receptor Agonist: From Screening to the Clinic Juan I. Luengo, GlaxoSmithKline, Collegeville, PA
9:45-10:15 a.m.	Coffee Break
10:15 a.m.-12:00 p.m.	Session 6: Chemistry in Support of Cancer Drug Discovery/Case Histories II
	Session Chairperson: Danzhou Yang, University of Arizona, Tucson, AZ DNA G-quadruplexes as Potential Anticancer Drug Targets Danzhou Yang The Discovery and Development of Diaryl-acylsulfonamide (ASAP): A Novel Class of Antitumor Agents for Solid Tumors Chuan Joe Shih, Eli Lilly Research Laboratories, Indianapolis, IN From HTS to Clinic: Discovery of PF-4217903 as Potent and Exquisitely Selective C-Met Inhibitor Jean Cui, Pfizer Global R & D, San Diego, CA
12:00 - 2:00 p.m.	Poster Session B and Light Lunch
2:00 – 3:45 p.m.	Session 7: Chemistry in Support of Cancer Drug Targeting, Drug Delivery, and Drug Disposition I
	Session Chairperson: To be announced Potent Immunoconjugates for Cancer Therapy Peter D. Senter, Seattle Genetics, Bothel, WA Chemical Modifications for Making Drugs out of RNA Interference Muthiah Manoharan, Alnylam, Cambridge, MA Title to be announced Representative from the laboratory of Kevin Foote, AstraZeneca, Inc., Macclesfield, United Kingdom
3:45 – 4:15 p.m.	Coffee Break
4:15 – 6:00 pm.	Session 8: Chemistry in Support of Cancer Drug Targeting, Drug Delivery, and Drug Disposition II
	Session Chairperson: Cheryl Zimmerman, University of Minnesota, Minneapolis, MN Multifunctional Nanotherapeutics for Cancer Treatment and Imaging Tamara Minko, Rutgers University, New Brunswick, NJ Surface-functionalization of Nanoparticles for Multi-targeted Drug Delivery Jayanth Panyam, University of Minnesota, Minneapolis, MN Folate Targeted Therapies for Cancer Christopher Leamon, Endocyte, West Lafayette, IN

February 11
7:00 – 8:00 a.m.	Continental Breakfast
8:00 – 9:45 a.m.	Session 9: Chemistry in Support of Cancer Drug Discovery and Development I
	Session Chairperson: David A. Wink, Jr., National Cancer Institute, Bethesda, MD Molecular Imaging Studies in Cancer Murali Krishna, National Cancer Institute, Bethesda, MD Role of Hyperpolarized C Spectroscopic Imaging in Drug Development John Kurhanewicz, University of California, San Francisco, San Francisco, CA Measuring Spatial and Temporal Molecular Changes in Tissues Using Mass Spectrometry Richard M. Caprioli, Vanderbilt University, Nashville, TN
9:45 – 10:15 a.m.	Coffee Break
10:15 a.m. - 12:00 p.m.	Session 10: Chemistry in Support of Cancer Drug Discovery and Development II
	Session Chairperson: John T. Hunt, Bristol-Myers Squibb, Princeton, NJ Synthesis and Scale-up of Sagopilone Johannes Platzek, Bayer Schering Pharma AG, Berlin, Germany Microheterogeneity and Analytical Approaches to Macromolecules Randal B. Bass, Amgen, Inc., Seattle, WA Systems and Controls for Handling Potent Anticancer Agents Rebecca Ahn, Ash Stevens, Inc., Detroit, MI
Departure